We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > REMAP-CAP

News List

Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients worldpharmanews
March 01, 2021
Treating critically ill COVID-19 patients with drugs typically used for rheumatoid arthritis may significantly improve survival, a landmark study has found.
Roche’s arthritis drug shows effectiveness for ill patients in Covid-19 trial pharmaceutical-technology
November 23, 2020
The UK’s Imperial College London has reported that early data from the REMAP-CAP trial showed Roche’s arthritis drug, Actemra (tocilizumab), is expected to reduce deaths and time spent in intensive care in critically ill patients with severe Covid-19.
Fast tracks testing of COVID-19 therapies worldpharmanews
April 14, 2020
A novel clinical trial developed by researchers at the University of Pittsburgh School of Medicine launched at UPMC to address one of the most important debates during the COVID-19 pandemic.